コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ific use as an antiviral, antibacterial, and antitumor agent.
2 s for the parent compound 1, a highly potent antitumor agent.
3 ved from Brassica vegetables, is a promising antitumor agent.
4 roliferative drug, and is considered a novel antitumor agent.
5 metic, for refractory cancer pain, and as an antitumor agent.
6 ing lead for development as an antibacterial/antitumor agent.
7 to enter Phase 1 human clinical trials as an antitumor agent.
8 )] in the bioactivation of this DNA-damaging antitumor agent.
9 6-one (ARC-111, topovale) is a new synthetic antitumor agent.
10 xicity of doxorubicin (DOX), a commonly used antitumor agent.
11 s that is currently in clinical trials as an antitumor agent.
12 -E1 vector has potential as a broad-spectrum antitumor agent.
13 us participating as an antiangiogenic and an antitumor agent.
14 potential as a replication-competent, viral antitumor agent.
15 or (IGF-IR/AS ODN) as an effective potential antitumor agent.
16 and dihydrofolate reductase (DHFR) and as an antitumor agent.
17 d analogue of 3a, was also synthesized as an antitumor agent.
18 as identified as a very selective and potent antitumor agent.
19 potential of a synthetic SIFalpha as a novel antitumor agent.
20 ess to 1,3-functionalized isoquinoline-based antitumor agent.
21 e used to support further developing of this antitumor agent.
22 the formal synthesis of neolamellarin A, an antitumor agent.
23 ICOS-Fc may act as an anti-inflammatory and antitumor agent.
24 is an oral serine/threonine kinase inhibitor antitumor agent.
25 und for further preclinical evaluation as an antitumor agent.
26 nhibitors of PKB therefore have potential as antitumor agents.
27 tic modulators with the potential for use as antitumor agents.
28 resistance by actively effluxing a number of antitumor agents.
29 assembly of the molecular framework of these antitumor agents.
30 drofolate reductase (DHFR) inhibitors and as antitumor agents.
31 ceptor (FR) alpha and beta substrates and as antitumor agents.
32 of SCF(Skp2) inhibitors as a novel class of antitumor agents.
33 tastasis) and in the resistance mechanism to antitumor agents.
34 of natural glycopeptides used clinically as antitumor agents.
35 deacetylase inhibitors (HDACI) are promising antitumor agents.
36 chemotherapeutic efficacy of platinum-based antitumor agents.
37 nd warrant development of these analogues as antitumor agents.
38 CDK4/cyclin D1 are attractive as prospective antitumor agents.
39 9761) is representative of a novel series of antitumor agents.
40 sunlight, environmental mutagens and certain antitumor agents.
41 selectivity characteristic of this class of antitumor agents.
42 exposure to bis-electrophiles such as common antitumor agents.
43 d stability and reactivity for this class of antitumor agents.
44 rugs of the duocarmycin and CC-1065 class of antitumor agents.
45 r SGLT2 inhibitors as potential antidiabetic/antitumor agents.
46 drofolate reductase (DHFR) inhibitors and as antitumor agents.
47 were designed, synthesized, and evaluated as antitumor agents.
48 of previously untreated tumors to cytotoxic antitumor agents.
49 sis of the cryptophycin/arenastatin class of antitumor agents.
50 D(P)H:quinone oxidoreductase (NQO1)-directed antitumor agents.
51 nobiotic compounds, including antifungal and antitumor agents.
52 em characteristic of the mitomycin family of antitumor agents.
53 des molecular underpinnings to develop novel antitumor agents.
54 in-polymerizing agents (MTPAs)) are powerful antitumor agents.
55 l]-l-glutamic acid (5), as TS inhibitors and antitumor agents.
56 es I and II are also targets for widely used antitumor agents.
57 S) and dihydrofolate reductase (DHFR) and as antitumor agents.
58 beneficial for design and targeting of novel antitumor agents.
59 protection and bioactivation of DNA-damaging antitumor agents.
60 been synthesized and evaluated as potential antitumor agents.
61 prevention and bioactivation of DNA-damaging antitumor agents.
62 tion with conventional chemotherapy or other antitumor agents.
63 gnificant potential to define a new class of antitumor agents.
64 nalogs were found to be potent antiviral and antitumor agents.
65 ic growth factors of tumors, show promise as antitumor agents.
66 ties, as an approach for producing effective antitumor agents.
67 lity of using proteasome inhibitors as novel antitumor agents.
68 r the development of new anti-angiogenic and antitumor agents.
69 examination of this or related promising new antitumor agents.
70 ogenic topo II cleavable complex-stabilizing antitumor agents.
71 king compounds have emerged as important new antitumor agents.
72 of the epithelium to many cell cycle-active antitumor agents.
73 generated the most highly and broadly active antitumor agents.
74 ls could potentially be useful for targeting antitumor agents.
75 on metabolic reduction of aziridinyl quinone antitumor agents.
76 nd AGF154 (7)] were synthesized as potential antitumor agents.
77 e reductive alkylation chemistry of mitosene antitumor agents.
78 t first step in the rational use of PUFAs as antitumor agents.
79 vity of gold(I) analogs of platinum-acridine antitumor agents.
80 G function, opening new targets for platinum antitumor agents.
81 ing them good targets for the development of antitumor agents.
82 monoepoxides may represent a novel class of antitumor agents.
83 duct biosynthesis, including antibiotics and antitumor agents.
84 oxidizing agents, including potent cytotoxic antitumor agents.
85 m an interesting target for the synthesis of antitumor agents.
86 bons and a benozyl ring in the side chain as antitumor agents.
87 narrow therapeutic indices of many of these antitumor agents.
88 (P)H:quinone oxidoreductase (NQO1) -directed antitumor agents.
89 he great potential of metal-NHC complexes as antitumor agents.
90 thiazole, 1a, 1b-g, are under development as antitumor agents.
91 and Ru) complexes containing NHC ligands as antitumor agents.
92 in and its analogues, are being evaluated as antitumor agents.
93 l be a superior targeted delivery system for antitumor agents.
94 ficacy and safety profile of these potential antitumor agents.
95 ld, therefore, have therapeutic potential as antitumor agents.
96 n a strategically very direct route to these antitumor agents.
97 tic modulators with the potential for use as antitumor agents.
98 benzo[a]phenoxazine derivatives as potential antitumor agents.
99 This paper describes microencapsulation of antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BC
100 ough the reaction of adenine in DNA with the antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea, a
103 cesses with similar kinetic efficiencies the antitumor agents 2-crotonyloxymethyl-2-cyclohexenone (CO
108 ural product is a highly potent and specific antitumor agent against MCF-7 (breast carcinoma) cell li
111 ulfonamides were recently reported as potent antitumor agents against a broad spectrum of human tumor
113 ,3-dihydro-1,3,4-oxadiazole (GLB) is a novel antitumor agent and belongs to glycosylated spiro-hetero
114 e results demonstrated that cGAMP is a novel antitumor agent and has potential applications in cancer
117 the efficacy of a soluble wnt receptor as an antitumor agent and suggests that further development of
118 e may provide a target for the anthracycline antitumor agents and a candidate ferricyanide reductase
119 etics, such as PG545, have been developed as antitumor agents and are designed to suppress angiogenes
121 an additional role in DNA damage response to antitumor agents and is associated with integrity of the
122 he resistance of glioma cells to a number of antitumor agents and the highly invasive nature of gliom
124 iocoraline-, azinomycin-, and bleomycin-like antitumor agents; and a rapamycin-like immunosuppressant
125 eral strategy for the total synthesis of the antitumor agent apoptolidin (1) is proposed, and the che
130 has been found previously to be an effective antitumor agent attributable to deprivation of the extra
132 ese findings suggest that aziridinyl quinone antitumor agents based on indoles will be rapidly inacti
133 oflavones have been synthesized as potential antitumor agents based on structural similarities to kno
135 documented tumor targeting properties of the antitumor agent bleomycin (BLM) were studied in cell cul
139 (CHK1) are of current interest as potential antitumor agents, but the most advanced inhibitor series
140 deacetylase (HDAC) inhibitors are promising antitumor agents, but they have not been extensively exp
141 modulator of the activity of antimetabolite antitumor agents by virtue of its inhibition of nucleosi
142 of lidamycin (C-1027), a clinically relevant antitumor agent, by Streptomyces globisporus that negati
145 The alpha-amino acid ester prodrugs of the antitumor agent camptothecin and a more potent, lipophil
146 rase I may be explored in the development of antitumor agents capable of targeting different aspects
148 PTX, an antimicrotubule agent, is a potent antitumor agent commonly used in the treatment of advanc
149 ith gemcitabine is much more effective as an antitumor agent compared with either agent alone in our
152 A processable total synthesis of a potent antitumor agent, desoxyepothilone F (dEpoF, 21-hydroxy-1
154 studies centered on the naturally occurring antitumor agent dictyostatin have recently identified se
155 first total syntheses of naturally occurring antitumor agents disorazoles A1 and B1 and the full stru
156 lts suggest that SelCID-3 represents a novel antitumor agent distinct from thalidomide and from previ
157 shown that hedamycin, a GC-rich DNA-binding antitumor agent, downregulates survivin transcription.
160 Although Fatostatin has been viewed as an antitumor agent due to its inhibition of SREBP and its e
161 ncer therapy; GGTase I inhibitors (GGTIs) as antitumor agents; effects of FTIs and GGTIs on cell cycl
162 -fluorobenzothiazole (5F-203) is a candidate antitumor agent empirically discovered with the aid of t
165 In this paper, we demonstrate that the novel antitumor agents farnesyltransferase inhibitors (FTIs) a
167 st cancer, and introduce Mesd as a promising antitumor agent for treating breast cancer subtypes with
170 y consequential for the development of viral antitumor agents for RCC and other CAR-negative tumors.
171 sible utility of trisubstituted acridines as antitumor agents for the disruption of both telomerase-d
172 rdenolides were identified as a new class of antitumor agents for the treatment of retinoblastoma.
173 l of proteasome inhibitors, a novel class of antitumor agents, for the treatment of retinoblastoma.
174 The first total synthesis of the potent antitumor agent fostriecin (CI-920) is described, confir
177 vesicular stomatatis virus (VSV) as a potent antitumor agent has made a dissection of the molecular d
179 )-crassalactone D (4), a naturally occurring antitumor agent, has been achieved by employing an oxida
184 iverse range of substrates including peptide antitumor agents, hormones, cyclic peptide antibiotics,
185 of DNA damage induced by many antiviral and antitumor agents; however, it remains undefined how (S)G
186 ave been proposed in the design of selective antitumor agents; however, little information is availab
187 The total synthesis of the lichen-derived antitumor agent hybocarpone (1) and related compounds is
188 as well as a variety of other drugs such as antitumor agents, immunosuppressants and antifungals.
189 a candidate for additional development as an antitumor agent in breast and other HER-2-dependent canc
190 inical proof-of-concept for BMS-754807 as an antitumor agent in combination with hormonal therapies i
191 Although it is a potent antiangiogenic and antitumor agent in many transplanted murine tumor models
195 s potential role as an immunosuppressant and antitumor agent in the management of cancer are also dis
196 he potential of DMDD as a safe and effective antitumor agent in the treatment of late-stage breast ca
197 ort the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer d
198 ata demonstrate that TRAIL alone is a potent antitumor agent in vivo, and its activity can be signifi
204 antiinflammatory/immunosuppressive drugs and antitumor agents in several types of lymphoma and leukem
208 low COMPARE correlations with known standard antitumor agents indicate a unique mechanism of action.
211 rolo[2,1-c][1,4]benzodiazepine (PBD) monomer antitumor agents is reported, establishing the molecular
212 tabolites, is an antimicrobial and potential antitumor agent isolated from Streptomyces nodosus subsp
213 (SAHA) is currently in clinical trials as an antitumor agent; it inhibits the activity of histone dea
217 osine kinases being developed as therapeutic antitumor agents may also have significant immunologic e
218 c acids derived from the amido groups of the antitumor agents mitozolomide and temozolomide have been
221 43 (ET-743), a highly promising marine-based antitumor agent presently in phase II clinical trials, h
222 n is an aureolic acid-type antimicrobial and antitumor agent produced by Streptomyces argillaceus.
223 d polyketide (PK)/nonribosomal peptide (NRP) antitumor agents, provides an ideal system to study a hy
225 competition, we discovered an analog of the antitumor agent rebeccamycin, a member of the increasing
229 l synthesis of the rare but extremely potent antitumor agent shishijimicin A has been achieved via a
230 se C inhibitor D-erythro-sphinganine and the antitumor agent (+)-spisulosine, whereas the Overman rea
232 trast, benzoquinone-based aziridinyl quinone antitumor agents such as AZQ, DZQ, and the new benzoquin
233 involved in the transport of platinum-based antitumor agents such as cisplatin (CDDP); however, the
234 linking two strands of DNA and are formed by antitumor agents such as cisplatin and nitrogen mustards
240 ch for the construction of the potent marine antitumor agents (+)-tedanolide (1) and (+)-13-deoxyteda
241 ated the cytotoxicity of the monomethylating antitumor agent Temozolomide by approximately 3- and 10-
242 rose, an unusual sugar found attached to the antitumor agent tetrocarcin A or the antibiotic kijanimi
243 AF was found to be a potent and effective antitumor agent that caused tumor regression in the MDA-
245 UCN-01 (7-hydroxystaurosporine) is a potent antitumor agent that exerts its effects through the inhi
246 ults suggest that Metastatin is an effective antitumor agent that exhibits antiangiogenic activity.
247 struction of novobiocin, a clinically useful antitumor agent that has been shown to inhibit both type
249 l curcumin-related compound EF24 is a potent antitumor agent that induces caspase-mediated apoptosis
252 Our findings indicate that EF24 is a potent antitumor agent that inhibits tumor growth and metastasi
256 Discodermolide is a potentially important antitumor agent that stabilizes microtubules and blocks
257 Furthermore, aurothiomalate is an effective antitumor agent that targets the tumor-initiating stem c
259 Histone deacetylase (HDAC) inhibitors are antitumor agents that also have antiinflammatory propert
262 ne ansamycins (BQAs) are a valuable class of antitumor agents that serve as inhibitors of heat shock
263 so as novel chemical matter that may lead to antitumor agents that specifically interfere with cancer
264 em for dissecting the mechanism of action of antitumor agents that target type II DNA topoisomerases.
268 esulting from one-electron activation of the antitumor agent tirapazamine by the enzymes xanthine/xan
269 is among the most highly and broadly active antitumor agents to have been evaluated in our laborator
270 is among the most highly and broadly active antitumor agents to have been evaluated in our laborator
271 rlotinib with OSU-03012, a celecoxib-derived antitumor agent, to overcome EGFR inhibitor resistance i
272 d total synthesis of the naturally occurring antitumor agents trioxacarcins is described, along with
273 A disodium phosphonooxymethyl prodrug of the antitumor agent triptolide was prepared from the natural
276 ynthesis of novel unsymmetrical bifunctional antitumor agents was accomplished by linking an imidazoa
277 ng of the mechanism of action of CM101 as an antitumor agent, we examined the role of the inflammator
280 zed abasic sites that are produced by potent antitumor agents were shown to inactivate DNA polymerase
281 ibitor entinostat is emerging as a promising antitumor agent when added to the standard-of-care treat
282 etic novel alkylphospholipid, a new class of antitumor agents which targets cell membranes and inhibi
283 developed OSU-2S, a novel PKCdelta-targeted antitumor agent, which is devoid of S1P1 receptor activi
284 d here represents a novel class of potential antitumor agents, which potently and selectively inhibit
286 yl)benzamide (CB30865) is a quinazolin-4-one antitumor agent whose high growth-inhibitory activity (W
290 conclusion, TF-011-MMAE is a promising novel antitumor agent with potent activity in xenograft models
291 kylphospholipids (ALKs) are a novel class of antitumor agents with an unknown mechanism of action.
292 ndicate that dEpoB and dEpoF are efficacious antitumor agents with both a broad chemotherapeutic spec
293 d as part of our program to provide targeted antitumor agents with folate receptor (FR) cellular upta
296 3-desoxyepothilone B (dEpoB), a new class of antitumor agents with promising in vivo preclinical prop
300 f anti-inflammatory ([ZrO](2+)[BMP](2-)) and antitumor agents ([ZrO](2+)[FdUMP](2-)) with an up to 80
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。